Allogeneic CAR T Cell Therapies for Leukemia - R1

American Journal of Hematology - United States
doi 10.1002/ajh.25399
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

CAR-T Cells and Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Immunotherapy
OncologyAllergyImmunology
2017English

Improving CAR T Cell Immunotherapy–mediated Remissions for Pediatric Leukemia

Journal of Clinical Investigation
Medicine
2019English

CAR T Cells for Acute Lymphoblastic Leukemia

American Journal of Hematology
Hematology
2019English

Pcn301 - Health Technology Assessment for Chimeric Antigen Receptor (Car) T-Cell Therapies for Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Extramedullary Relapse of Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation Treated by CAR T-Cell Therapy: A Case Report

OncoTargets and Therapy
OncologyPharmacology
2018English

Role of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia

Memo - Magazine of European Medical Oncology
OncologyHematology
2019English

Accelerating CAR Therapy in CLL: The Development and Challenges of CAR T Cell Therapy for Chronic Lymphocytic Leukemia

American Journal of Hematology
Hematology
2019English

Primary Bone Tumors: Challenges and Opportunities for CAR‐T Therapies

Journal of Bone and Mineral Research
EndocrinologyOrthopedicsSports MedicineMetabolismDiabetes
2019English

CTL019 (Tisagenlecleucel): CAR-T Therapy for Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy